Back to News
Market Impact: 0.2
Korro Bio Announces Preclinical Results for KRRO-111
Source: Nasdaq
Healthcare & BiotechTechnology & Innovation
Korro Bio announced preclinical results for KRRO-111, a development candidate being studied as a potential treatment for Alpha-1 Antitrypsin Deficiency. The company describes it as a proprietary GalNAc-conjugated RNA-editing oligonucleotide administered subcutaneously; the provided article excerpt contains no specific results or numerical data.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
KRRO0.40
More News
- Asia stocks fall as AI rout batters S.Korea; Japan spooked by strong CPI
- SK Hynix shares slide after chipmaker scraps Solidigm IPO plans
- Why is SK Hynix stock sliding today?
- Apple’s iPhone Duo Hits Stores in Face of Short Supply and High Demand
- Gold Holds Near Three-Month Low as AI Jitters Fuel Volatility
- OpenAI nears up to $30 billion funding round at $1.25 trillion valuation led by UAE investors
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AI Research Tools for Pension Funds and Allocators
- AllMind's Data Standardization Methodology: Our Approach to Fundamentals